Rationale Longitudinal data on the impact of continued, switched or discontinued antifibrotic
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …

There is no debate that idiopathic pulmonary fibrosis (IPF) is a devastating disease that has
a significant impact on patient morbidity and mortality. Patients with IPF experience …

Background To examine the relationship between body mass index (BMI) and mortality in
patients with idiopathic pulmonary fibrosis (IPF). Methods We studied a cohort of patients …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Patients with idiopathic pulmonary fibrosis (IPF) inevitably experience declines in functional
status that are most frequently due to progressive pulmonary fibrosis. However, the cause of …

Rationale Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung
disease that has no cure. Many current research efforts center on diagnostic and therapeutic …

Background Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic
interstitial pneumonias (IIPs) of unknown etiology that often affects male, elderly smokers …

In therapeutic studies in idiopathic pulmonary fibrosis (IPF), the low prevalence of significant
change in pulmonary functional tests (PFTs) has been a major constraint. The prognostic …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease associated with a
dismal prognosis and a median survival of approximately 3 years. However, in clinical …

Background Observational data under real-life conditions in idiopathic pulmonary fibrosis
(IPF) is scarce. We explored anti-fibrotic treatment, disease severity and phenotypes in …